EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy

Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.

A. O. Smith: Growth Re-Acceleration Supported By Strong Execution And Macro Recovery

A. O. Smith Corporation is rated a Buy with risk/reward attractive as growth and margins are set to accelerate from FY26.
TCTMD

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...
Frontiers

Advancements in Transcatheter Mitral Valve Repair and Replacement: Insights and Innovations

The advent of transcatheter mitral valve repair (TMVr) and replacement (TMVR) has marked a revolutionary shift in the management of mitral valve disease, ...